Citations

Showing 10 of 108104 citations.

Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors.
Hamid, Omid , Merriam, Priscilla , Seetharam, ­Mahesh , Vaishampayan, Ulka N. , Weroha, Saravut J., Krishnan, Suba, George, Angela , Vaishampayan, Ulka , McKean, Meredith Ann , Dumbrava, Ecaterina E. , Mettu, Niharika B , Call, Justin , Kapoun, Ann M. , Lucas, Jennifer

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 2651-2651

10.1200/jco.2022.40.16_suppl.2651 Get It

2651 Background: Etigilimab (etig), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (poliovirus receptor) and inhibits downstream signalling with target cell killing. Etig +/- nivolumab (nivo) showed acceptable safety and preliminary activity in a FIH Phase 1a/b study in solid tumors. ACTIVATE, an open-label Phase 1b/2 basket study is evaluating further efficacy, safety, tolerability and PK/PD of etig+nivo. This is a preliminary efficacy and safety analysis from ACTIVATE. Methods: Subjects with advanced/metastatic solid tumors without curative/standard of care therapies are given IV etig+nivo Q2W until disease progression or intolerable toxicity. Six open cohorts are enrolling in parallel: endometrial cancer (post-front-line platinum), endometrial cancer (2-3 prior lines), PD-L1+ checkpoint-inhibitor-naïve (CPI-n) cervical cancer, rare cancers (germ cell tumor (GCT), sarcoma, uveal melanoma), ovarian cancer (post-front-line platinum) and TMB-h/MSS, (TMB >10mut/mb) tumors. Tumor assessments are done every 8 weeks following baseline scan. Primary endpoint is investigator-assessed ORR by RECIST 1.1. Secondary endpoints include duration of response and safety. Results: Of 27 efficacy-evaluable subjects enrolled in the 6 open cohorts with minimum 1 staging scan or radiological/clinical progression at data cut-off of 02/10/22, 12 had clinical benefit with 1 complete response (CR), 2 partial responses (PRs) and 9 stable diseases (SDs) and 15 had radiological/clinical progressive disease (PD), with an overall response rate (ORR) of 11% and disease control rate (DCR) of 44%. Conclusions: Etig+nivo is safe and well tolerated with no new safety signals. Early efficacy was noted in cervical cancer (1CR, 1PR and 1SD) and uveal melanoma (3 SDs >20 weeks). Encouraging activity was also noted in ovarian cancer and post-CPI treated TMB-H/MSS NSCLC. These early data support continued evaluation of the combination of etig+nivo. Clinical activity was notable as below. Clinical trial information: NCT04761198. [Table: see text]
A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody.
Patnaik, Amita , Tan, Winston , Jahchan, Nadine S. , Pierce, Kristen J. , Li, Yunfeng , Reyno, Len, Chamberlain, Marc C. , Hamilton, Erika , Winer, Ira Seth , Hubbard, Joleen M. , Schenk, Erin L. , Sonbol, Mohamad Bassam , Pierce, Kristen

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 2648-2648

10.1200/jco.2022.40.16_suppl.2648 Get It

2648 Background: To characterize the safety and tolerability of PY314, an immunosuppressive macrophage depleting antibody, as a single agent and in combination with pembrolizumab in subjects with advanced refractory solid tumors including subject’s refractory to checkpoint inhibitors if approved for that indication. Methods: Two were evaluated in subjects with advanced solid tumors, single agent PY314 and PY314 in combination with 200 mg of pembrolizumab using a 3+3 dose escalation study design. Dosing was intravenous and administered once every 3-weeks, a defined cycle. Disease assessment by RECIST 1.1 was performed every 6 weeks. Each stratum included 4 dose levels of PY314 (1, 3, 10, and 20 mg/kg). Pharmacokinetics were evaluated at specified time points. Archival tumor tissue was analyzed for TREM2 expression by immunohistochemistry. Based on preclinical evaluation of TREM2 expression, HR+ HER2- and triple negative breast cancer, colorectal cancer, renal cell cancer, non-small cell lung cancer and gynecologic cancers were studied. Results: 28 subjects (median age 60 years [range 26-76], 22 females and 6 ) with an ECOG PS <2 were enrolled and all, but one was (1 subject withdrew consent after dosing). 15 subjects were treated with single agent PY314 and 13 were treated with the combination. No infusion-related reactions, dose limiting toxicities, suspected unexpected serious adverse reactions or high-grade treatment related adverse events (TRAEs) that resulted in treatment discontinuance was seen. 12 subjects experienced at least one TRAE, and in all but one subject, these were low grade. One subject experienced a treatment-related immune system disorder. serious adverse events, all unrelated to treatment. TREM2 expression in archival tumor ranged from 0.0-20%. PY314 pharmacokinetics were linear, dose proportional, unaffected by concomitant pembrolizumab and with a half-life of 8-9 days. Best radiographic response was stable disease seen in 11 subjects (39.3%) ranging in duration from 9-42 weeks. 6 subjects with stable disease have progressed and 5 remain on treatment. Conclusions: PY314 was well tolerated and has an excellent safety profile both as a single agent and in combination with pembrolizumab. A recommended dose for expansion was derived and enrollment in five prespecified cancers is ongoing. Clinical trial information: 04691375.
Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.
Winklhofer, Sebastian , Lmalem, Hafida, Brandsma, Dieta , Kumthekar, Priya , Jaeckle, Kurt A. , Glantz, Michael , Wen, Patrick Y. , colleagues, EORTC RANO LM scorecard task force, including 38, Rhun, Émilie Le , Devos, Patrick , Smits, Marion , Tonn, Joerg-Christian , Preusser, Matthias , Wen, Patrick Yung , Bendszus, Martin , Weller, Michael , colleagues, EORTC RANO LM scorecard task force, including 38

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 2026-2026

10.1200/jco.2022.40.16_suppl.2026 Get It

2026 Background: Validation of the 2016 RANO MRI scorecard for leptomeningeal metastasis failed for multiple reasons. Accordingly, this joint EORTC Brain Tumor Group and RANO effort sought to prospectively validate a revised MRI scorecard for response assessment in leptomeningeal metastasis. Methods: Coded paired cerebrospinal MRI of 20 patients with leptomeningeal metastases from solid cancers at baseline and follow-up after treatment and instructions for assessment were provided via the EORTC imaging platform. The Kappa coefficient was used to evaluate the inter-observer pairwise agreement. Results: Thirty-five raters participated, including 9 neuroradiologists, 17 neurologists, 4 radiation oncologists, 3 neurosurgeons and 2 medical oncologists. Among single leptomeningeal metastases-related imaging findings at baseline, the best median concordance was noted for hydrocephalus (Kappa = 0.63), and the worst median concordance for spinal linear enhancing disease (Kappa = 0.46). The median concordance of raters for the overall response assessment was moderate (Kappa = 0.44). Notably, the interobserver agreement for the presence of parenchymal brain metastases at baseline was fair (Kappa = 0.29) and virtually absent for their response to treatment. 394 of 700 ratings (20 patients x 35 raters, 56%) were fully completed. In 308 of 394 fully completed ratings (78%), the overall response assessment perfectly matched the summary interpretation of the single ratings as proposed in the scorecard instructions. Conclusions: This study confirms the principle utility of the new scorecard, but also indicates the need for training of MRI assessment with a dedicated reviewer panel in clinical trials. Electronic case report forms with “blocking options” may be required to enforce completeness and quality of scoring.
Association of neighborhood socioeconomic disadvantage and cognitive impairment
Vassilaki, Maria , Aakre, Jeremiah A. , Castillo, Anna , Wilson, Patrick M. , Kremers, Walter K. , Geda, Yonas E. , Alhurani, Rabe E., Graff‐Radford, Jonathan , Vemuri, Prashanthi , Lowe, Val J. , Petersen, Ronald C. , Vemuri, Prashanthi , Geda, Yonas E , Castillo, Anna M , Kremers, Walter K , Chamberlain, Alanna M. , Mielke, Michelle M. , Machulda, Mary M. , Jack, Clifford R. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | June 6, 2022 | Volume: 19 | Issue: 3 | Pages: 761-770

10.1002/alz.12702 | PMID 35666244 Get It

AbstractIntroductionWe investigated the association of the area deprivation index (ADI) with cognitive decline, mild cognitive impairment (MCI), and dementia in older adults (≥50 years old). ADI is a neighborhood socioeconomic disadvantage measure assessed at the census block group level.MethodsThe study included 4699 participants, initially without dementia, with available ADI values for 2015 and at least one study visit in 2008 through 2018. Using logistic regression and Cox proportional hazards models with age as the time scale, we assessed the odds for MCI and the risk for dementia, respectively.ResultsIn cognitively unimpaired (CU) adults at baseline, the risk for progression to dementia increased for every decile increase in the ADI state ranking (hazard ratio = 1.06, 95% confidence interval (1.01–1.11), P = .01). Higher ADI values were associated with subtly faster cognitive decline.DiscussionIn older CU adults, higher baseline neighborhood socioeconomic deprivation levels were associated with progression to dementia and slightly faster cognitive decline.Highlights The study used area deprivation index, a composite freely available neighborhood deprivation measure. Higher levels of neighborhood deprivation were associated with greater mild cognitive impairment odds. Higher neighborhood deprivation levels were associated with higher dementia risk.
19 Signal averaged ecg changes in hypertrophic cardiomyopathy with obstructive sleep apnoea
Venkataraman, Shreyas , Karim, Shahid , Chahal, C. Anwar A. , Somers, Virend K.

Mayo Clinic

ACHD/Valve disease/Pericardial disease/Cardiomyopathy | June 6, 2022 | Volume: No volume available | Issue: No issue available | Pages: A16-A17

10.1136/heartjnl-2022-bcs.19 Get It

14 Impact of epilepsy or seizures on outcomes following takotsubo cardiomyopathy
Sawatari, Hiroyuki , Wafa, Syed Emir Irfan , Padmanabhan, Deepak , Ahmed, Raheel , Deshpande, Saurabh , Khanji, Mohammed Y , Somers, Virend K. , Chahal, C. Anwar A.

Mayo Clinic

ACHD/Valve disease/Pericardial disease/Cardiomyopathy | June 6, 2022 | Volume: No volume available | Issue: No issue available | Pages: A11.2-A12

10.1136/heartjnl-2022-bcs.14 Get It

13 The long-term effects of adipose depot change following bariatric surgery on cardiac geometry
Henry, John A. , Abdesselam, Inès, Sorimachi, Hidemi, Rayner, Jenny, Deal, Oscar , Byrne, James V. , Byrne, James, Neubauer, Stefan , Borlaug, Barry A. , Rider, Oliver J.

Mayo Clinic

ACHD/Valve disease/Pericardial disease/Cardiomyopathy | June 6, 2022 | Volume: No volume available | Issue: No issue available | Pages: A11.1-A11

10.1136/heartjnl-2022-bcs.13 Get It

Risk of COPD exacerbation is increased by poor sleep quality and modified by social adversity
Baugh, Aaron , Buhr, Russell G. , Quibrera, P. Miguel, Kaufman, Joel D. , Koch, Abigail L. , Mkorombindo, Takudzwa , Namen, Andrew M. , Ortega, Victor E. , Paine, Robert , Peters, Stephen P. , Schotland, Helena , Zeidler, Michelle , Hansel, Nadia N. , Woodruff, Prescott G. , Kaufman, Joel D , Ortega, Victor, Baugh, Aaron D , Buhr, Russell G , Barjaktarević, Igor , Barr, R. Graham , Bowler, Russell P. , Han, MeiLan King , Krishnan, Jerry A , Labaki, Wassim W. , Martínez, Fernando J. , Sundar, Krishna M. , Thakur, Neeta

Mayo Clinic

Sleep | June 6, 2022 | Volume: 45 | Issue: 8 | Pages: No page available

10.1093/sleep/zsac107 | PMID 35665826 Get It

Abstract Study Objectives Sleep is an important dimension in the care of chronic obstructive pulmonary disease (COPD), but its relevance to exacerbations is unclear. We wanted to assess whether sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI) is associated with an increased risk of COPD exacerbations and does this differ by socio-environmental exposures. Methods We included 1647 current and former smokers with spirometrically confirmed COPD from the SPIROMICS cohort. We assessed incidence rate ratios for exacerbation using zero-inflated negative binomial regression adjusting for demographics, medical comorbidities, and multiple metrics of disease severity, including respiratory medications, airflow obstruction, and symptom burden. Our final model adjusted for socio-environmental exposures using the Area Deprivation Index, a composite measure of contemporary neighborhood quality, and Adversity–Opportunity Index, a composite measure of individual-level historic and current socioeconomic indicators. We used a pre-determined threshold of 20% missingness to undertake multiple imputation by chained equations. As sensitivity analyses, we repeated models in those with complete data and after controlling for prior exacerbations. As an exploratory analysis, we considered an interaction between socio-environmental condition and sleep quality. Results After adjustment for all co-variates, increasing PSQI scores (range 0–21) were associated with a 5% increased risk for exacerbation per point (p = .001) in the imputed dataset. Sensitivity analyses using complete cases and after controlling for prior exacerbation history were similar. Exploratory analysis suggested less effect among those who lived in poor-quality neighborhoods (p-for-interaction = .035). Conclusions Poor sleep quality may contribute to future exacerbations among patients with COPD. This represents one target for improving disease control. Clinical Trial Registration Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). ClinicalTrials.gov Identifier# NCT01969344. Registry URL: https://clinicaltrials.gov/ct2/show/.
Demographic and clinical characteristics of hospitalized psoriasis patients
Ijadi, Fatemeh, Nasimi, Maryam , Oskouie, Iman Menbari , Rahimdoost, Nazanin, Hatami, Parvaneh , Aghazadeh, Nessa , Nasimi, Maryam , Hatami, Parvaneh , Aghazadeh Mohandesi, Nessa , Aryanian, Zeinab , Mahmoudi, Hamidreza

Mayo Clinic

Journal of Cosmetic Dermatology | June 6, 2022 | Volume: 21 | Issue: 11 | Pages: 6476-6478

10.1111/jocd.15144 | PMID 35665588 Get It

Combining medical and surgical management strategies for hidradenitis suppurativa: Need for a treat to target approach
Goldberg, Stephanie R. , Alavi, Afsáneh , Naik, Haley B. , Alavi, A , Lowes, Michelle A

Mayo Clinic

Dermatological Reviews | June 6, 2022 | Volume: 3 | Issue: 3 | Pages: 123-125

10.1002/der2.108 Get It

AbstractFor optimal management of hidradenitis suppurativa (HS), we propose a treat‐to‐target approach that synergizes medical and surgical therapies to improve outcomes and health‐related quality of life for HS patients. Studies are required to define the optimal targets in HS, however, proposed targets include disease remission or low disease activity. The goals of medical therapy in HS are to reduce existing inflammation and to prevent disease progression. The goals of surgical therapy are removal of permanently damaged fibrotic tissue and removal of biofilm within tunnels. In a treat‐to‐target approach, medical and surgical modalities are combined to optimize HS management. Regular and close monitoring are required to assess treatment response and achieve the predetermined target. Adjustments to the treatment plan can be made until the predetermined target is achieved. Research is needed to establish and evaluate this treat‐to‐target approach to help patients improve quality of life and achieve optimal disease control, and ultimately, disease remission.